-
公开(公告)号：KR1020160120503A
公开(公告)日：2016-10-18
申请号：KR1020150049649
申请日：2015-04-08
Applicant: 동화약품주식회사
IPC: A61K9/20 , A61K9/00 , A61K31/415
Abstract: 본발명은활성성분으로쎄레콕시브(Celecoxib), 이의약학적으로허용하는염 또는이의전구약물(Prodrug)을포함하는속방출구획및 지연방출구획을포함하는약제학적제제를제공한다. 본발명의제제는약물의방출을이분화하여고농도의급속한방출로발생하는부작용을방지하고, 약물의혈중농도를조절함으로써약물의효과를극대화하여환자의복용을용이하게하는효과를나타낸다.
-
公开(公告)号：KR101616928B1
公开(公告)日：2016-05-02
申请号：KR1020100001379
申请日：2010-01-07
Applicant: 동화약품주식회사
IPC: C07D495/04 , A01N43/90 , C07D403/14
CPC classification number: C07D495/04
Abstract: 본발명은클로피도그렐자유염기를 2-부탄올과클로피도그렐자유염기중량기준으로 4 내지 14%의물을함유하는혼합용매하에서진한황산과반응시켜클로피도그렐황산수소염의결정형(I)을제조하는방법을제공한다.
-
公开(公告)号：KR1020150133433A
公开(公告)日：2015-11-30
申请号：KR1020140060112
申请日：2014-05-20
Applicant: 동화약품주식회사
IPC: C07D471/04 , C07D401/04 , C07D403/04
CPC classification number: C07D471/04 , C07D487/10
Abstract: 본발명은자보플록사신 D-아스파르트산염의개선된제조방법에관한것이다. 본발명은자보플록사신 D-아스파르트산염을제조하기위하여사용하는출발물질인 8-메톡시이미노-2,6-디아자-스피로[3,4]옥탄-2-카르복실산 t-부틸에스테르숙신산염(TBDCS) 또는 2-(2,2,2-트리플루오로-아세틸)-2,6-디아자-스피로[3.4]옥탄-8-온-메틸옥심메탄설폰산염(TDMOS)의신규한제조방법을제공한다. 본발명에따른제조방법은상기출발물질을높은수율과높은품질(HPLC 순도; 99.5% 이상)로제조할수 있어, 대량생산에적합하며, 치환반응시 TBDCS나 TDMOS를 1.0~1.1 당량을사용하여획기적으로생산단가를절감할수 방법을제공하기때문에자보플록사신 D-아스파르트산염의대량생산에유용하게이용될수 있다.
Abstract translation: 本发明涉及一种制造扎布沙星D-天冬氨酸盐的改进方法。 本发明提供了制备用于制备扎布沙星D-天冬氨酸盐，8-甲氧基亚氨基-2,6-二氮杂 - 螺[3,4]辛烷-2-甲酸叔丁酯琥珀酸酯的引发剂的新方法 酸性盐（TBDCS）或2-（2,2,2-三氟 - 乙酰基）-2,6-二氮杂 - 螺[3,4]辛烷-8-对O-甲基肟甲磺酸盐（TDMOS）。 根据本发明的制造方法可以以高产率和质量（HPLC纯度;高于99.5％）制造引发剂，从而适合批量生产。 另外，该方法提供了在取代反应的情况下使用1.0〜1.1当量的TBDCS或者TDMOS来显着降低生产成本的方法，从而有效地用于批量生产扎布沙星D-天冬氨酸盐。
-
公开(公告)号：KR1020120111771A
公开(公告)日：2012-10-11
申请号：KR1020110027789
申请日：2011-03-28
Applicant: 동화약품주식회사
IPC: A61K36/605 , A61K31/36 , A61P3/10
CPC classification number: A61K31/352 , A23L33/10 , A61K31/05 , A61K31/353
Abstract: PURPOSE: A final glycosylation product inhibitor or health functional food is provided to suppress development of diabetic complication. CONSTITUTION: A final glycosylation product inhibitor which suppresses the development of diabetes complication contains mulberrofuran G isolated from Morus bark, mulberrofuran K, kuwanon G, kuwanon Z, oxyresveratrol, 2',4',5,7-tetrahydroxyflavanone, morusignin L, or dihydromorin as an active ingredient. The diabetic complication includes diabetic splenocyte nephritis, diabetic retinopathy or diabetic splenocyte neuropathic disease. [Reference numerals] (1) Normal group(-20°C); (10) Morusignin-L; (11) Dihydromorin; (2) Control group(37°C); (3) Pyridoxamine(positive control group); (4) Mulberrofuran-G; (5) Mulberrofuran-K; (6) Kuwanon-G; (7) Kuwanon-Z; (8) 2'.4'.5.7-tetrahydroxyflavanone; (9) Oxyresveratrol; (AA) Anti-AGEs antibody; (BB) Anti-CML antibody; (CC) Ponseau S staining
Abstract translation: 目的：提供最终的糖基化产物抑制剂或保健功能食品来抑制糖尿病并发症的发展。 构成：抑制糖尿病并发症发展的最终糖基化产物抑制剂含有从桑树皮，多杀龙furan酮K，kuwanon G，kuwanon Z，氧基白藜芦醇，2'，4'，5,7-四羟基黄烷酮，morusignin L或二氢肌醇 作为活性成分。 糖尿病并发症包括糖尿病性脾细胞性肾炎，糖尿病性视网膜病变或糖尿病脾细胞性神经病变。 （附图标记）（1）正常组（-20℃）; （10）Morusignin-L; （11）二氢吗啉; （2）对照组（37℃）; （3）吡哆胺（阳性对照组）; （4）芒果呋喃-G; （5）甲基呋喃-K; （6）Kuwanon-G; （7）Kuwanon-Z; （8）2'4'5.7-四羟基黄烷酮; （9）氧化维生素; （AA）抗AGEs抗体; （BB）抗CML抗体; （CC）Ponseau S染色
-
公开(公告)号：KR1020110094751A
公开(公告)日：2011-08-24
申请号：KR1020100014346
申请日：2010-02-17
Applicant: 동화약품주식회사
IPC: C07D403/10 , C07D403/04 , C07D403/06
CPC classification number: C07D403/04
Abstract: PURPOSE: A method for preparing telmisartan is provided to easily remove inorganic salt using a reaction solvent and to simplify reaction process without a separate process. CONSTITUTION: A method for preparing telmisartan of chemical formula 1 comprises: a step of condensing a compound of chemical formula 2 and a compound of chemical formula 3 using dimethyl sulfoxide and isopropanol to prepare a compound of chemical formula 4; and a step of hydrolyzing the compound of chemical formula 4 in a mixture solvent of methanol and purified water.
Abstract translation: 目的：提供替米沙坦制备方法，以便使用反应溶剂轻松除去无机盐，并简化反应过程，无需单独的工艺。 构成：化学式1的替米沙坦的制备方法包括：使用二甲基亚砜和异丙醇将化学式2的化合物与化学式3的化合物缩合以制备化学式4的化合物的步骤; 以及在甲醇和净化水的混合溶剂中水解化学式4的化合物的步骤。
-
Patent Agency Ranking
公开(公告)号：KR101047614B1
公开(公告)日：2011-07-07
申请号：KR1020080073710
申请日：2008-07-28
Applicant: 동화약품주식회사
IPC: C07D417/06 , C07D417/04 , C07D277/42
CPC classification number: C07D277/22 , C07D277/28 , C07D277/40 , C07D417/06
Abstract: 본 발명은 신규한 벤즈아미딘 유도체, 이의 제조방법 및 이를 포함하는 골다공증의 예방 또는 치료용 약학 조성물에 관한 것이다. 본 발명의 벤즈아미딘 유도체는 매우 낮은 농도에서 파골세포에 대한 분화를 효과적으로 억제하여 골다공증의 예방 또는 치료에 유용하게 사용될 수 있다.
-
107.发明公开
公开(公告)号：KR1020110054670A
公开(公告)日：2011-05-25
申请号：KR1020090111413
申请日：2009-11-18
Applicant: 동화약품주식회사
IPC: C07C253/00 , C07C255/40 , A61K31/277
Abstract: PURPOSE: A process for preparing 2-cyano-3-hydroxy-N-[(4-trifluoromethyl)phenyl]but-2-enamide is provided to easily remove by-products generated during the manufacturing process of final products. CONSTITUTION: A process for preparing 2-cyano-3-hydroxy-N-[(4-trifluoromethyl)phenyl]but-2-enamide of chemical formula 1 from a compound of chemical formula 5 comprises the steps of: activating a compound of chemical formula 2 to an esterified compound using a carbodiimide compound; and reacting the resultant with a compound of chemical formula 4 to prepare a compound of chemical formula 5. The carbodiimide compound is selected from 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride, 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide, 1,3-diisopropylcarbodiimide or 1,3-dicyclohexylcarbodiimide.
Abstract translation: 目的：提供2-氰基-3-羟基-N - [（4-三氟甲基）苯基]丁-2-烯酰胺的制备方法，以便容易地除去最终产品的制造过程中产生的副产物。 构成：由化学式5的化合物制备化学式1的2-氰基-3-羟基-N - [（4-三氟甲基）苯基]丁-2-烯酰胺的方法包括以下步骤：活化化学式 式2与使用碳二亚胺化合物的酯化化合物反应; 将所得物与化学式4的化合物反应，制备化学式5的化合物。碳二亚胺化合物选自1- [3-（二甲基氨基）丙基] -3-乙基碳二亚胺盐酸盐，1- [3-（二甲基氨基） 丙基] -3-乙基碳二亚胺，1,3-二异丙基碳二亚胺或1,3-二环己基碳二亚胺。
-
-
-
-
-
-
-
Search Results
465
records
(took 0.03 seconds)
